News

Under the terms of this agreement, Engitix and Takeda will collaborate in the confirmation and validation of targets and preclinical development of therapeutics in liver fibrosis using Engitix’s

AstraZeneca has initiated a phase 1 trial of a monoclonal antibody combination called AZD7442, which is being developed for the prevention and treatment of Covid-19. Dubbed as NCT04507256,

The Minister of Foreign Affairs of Indonesia, H.E. Retno LP Marsudi and Minister of State Owned-Companies of Indonesia, H.E. Erick Thohir witnessed the signing of the two agreements.

As part of the deal, Acadia has purchased all of the outstanding shares of CerSci for $52.5m in the form of its stock. CerSci shareholders are also eligible

CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel, an investigational, orally administered taxane, in patients with MBC. CONTESSA is comparing tesetaxel dosed orally at 27

The manufacturing of the AZD1222 vaccine candidate will be taken up at Catalent’s commercial gene therapy manufacturing plant in Harmans, Maryland. Catalent said that it will prepare the

“We are excited to complete our first regulatory submission for CABOMETYX in combination with an immune-checkpoint inhibitor based on the positive results from the CheckMate -9ER phase 3

Forbius is engaged in the designing and development of advanced biotherapeutics to treat cancer and fibrotic diseases. The company has developed a portfolio of selective and potent inhibitors

The trial was conducted among untreated patients with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone. “While the